/
ANRO
$32.30+$3.12 (+10.69%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
39M shares
52-week range
$3.02 – $33.67
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Change+$11.60
Alto Neuroscience Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
www.altoneuroscience.com- Employees
- 68
- IPO / List date
- Feb 2, 2024
- HQ
- MOUNTAIN VIEW, CA
Held by traders on TradeandTell
No one on the platform currently holds ANRO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 103,499 | $2.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANRO yet.
